AOD-9604 vs MK-677
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, AOD-9604 or MK-677?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between AOD-9604 and MK-677?
MK-677 is an oral non-peptide ghrelin receptor agonist producing sustained GH elevation; AOD-9604 is an injectable GH fragment peptide targeting lipolysis without GH elevation - oral vs. injectable, GH-elevating vs. non-GH-elevating.
Evidence Comparison
MK-677 (ibutamoren): multiple Phase 2 studies characterizing GH/IGF-1 elevation, body composition effects, and sleep quality (Nass et al. 2008, J Clin Endocrinol Metab). AOD-9604: negative Phase 3 for obesity. MK-677 has more positive human pharmacological data, though neither is approved.
Evidence Context Favoring AOD-9604
GH-independent lipolysis research using a GH fragment, acknowledging the Phase 3 failure.
Evidence Context Favoring MK-677
GH/IGF-1 elevation research with oral bioavailability advantage, accepting the ghrelin-related appetite increase side effect.
Side-by-Side Snapshot
| Evidence grade | AOD-9604: Level D MK-677: Level B |
|---|---|
| Research status | AOD-9604: Preclinical MK-677: Phase 3 |
| Primary category | AOD-9604: Weight Loss & Metabolic MK-677: Growth Hormone |
| Cited studies | AOD-9604: 2 MK-677: 4 |